<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003239</url>
  </required_header>
  <id_info>
    <org_study_id>DM97-229</org_study_id>
    <secondary_id>U01CA070172</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <secondary_id>MDA-DM-97229</secondary_id>
    <secondary_id>MDA-FDR001791</secondary_id>
    <secondary_id>NCI-T97-0105</secondary_id>
    <secondary_id>CDR0000066114</secondary_id>
    <nct_id>NCT00003239</nct_id>
  </id_info>
  <brief_title>Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia</brief_title>
  <official_title>Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Alpha Interferon (IFN-A), Low-Dose Cytosine Arabinoside (ARA-C), and Homoharringtonine (HHT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
      so they stop growing or die. Combining biological therapy with chemotherapy may kill more
      cancer cells.

      PURPOSE: Phase II trial to study the effectiveness of chemotherapy with cytarabine and
      homoharringtonine and biological therapy with interferon alfa in treating patients with
      chronic phase chronic myelogenous leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the effectiveness of low dose cytarabine, homoharringtonine, and
      interferon alfa in stimulating a complete cytogenic response in patients with Philadelphia
      chromosome positive early chronic phase chronic myelogenous leukemia. II. Evaluate the
      duration of the cytogenic response in these patients after this treatment. III. Determine
      differential success rates and analyze results by prognostic subsets (e.g., risk group,
      splenomegaly, thrombocytosis, age, etc.) in this patient population.

      OUTLINE: Patients receive debulking therapy consisting of hydroxyurea until blood count is at
      proper level. Patients then receive interferon alfa and cytarabine daily by subcutaneous
      injection. Homoharringtonine is administered by continuous infusion on days 1-5. Treatment
      continues for 5-7 years in the absence of unacceptable toxicity or disease progression
      (accelerated or blastic phase CML). If complete remission is achieved, peripheral blood stem
      cells are collected. Patients are followed every 3 months for the first year and every 6
      months thereafter.

      PROJECTED ACCRUAL: A total of 100 patients will be accrued for this study within 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1998</start_date>
  <completion_date type="Actual">October 2001</completion_date>
  <primary_completion_date type="Actual">October 2001</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients with Complete Cytogenic Response</measure>
    <time_frame>Every 3 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Chemotherapy with Cytarabine + Homoharringtonine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interferon alfa and cytarabine daily by subcutaneous injection. Homoharringtonine is administered by continuous infusion on days 1-5.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant Interferon Alfa</intervention_name>
    <description>Daily by subcutaneous injection.</description>
    <arm_group_label>Chemotherapy with Cytarabine + Homoharringtonine</arm_group_label>
    <other_name>Interferon Alpha 2-A</other_name>
    <other_name>Roferon-A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Daily by subcutaneous injection.</description>
    <arm_group_label>Chemotherapy with Cytarabine + Homoharringtonine</arm_group_label>
    <other_name>Ara-C</other_name>
    <other_name>DepotCyt</other_name>
    <other_name>Cytosine Arabinosine Hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omacetaxine Mepesuccinate</intervention_name>
    <description>Homoharringtonine is administered by continuous infusion on days 1-5.</description>
    <arm_group_label>Chemotherapy with Cytarabine + Homoharringtonine</arm_group_label>
    <other_name>CGX-635-CML-202</other_name>
    <other_name>HHT</other_name>
    <other_name>Homoharringtonine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Cytologically confirmed early chronic phase chronic myelogenous
        leukemia (CML) Diagnosed within 12 months Philadelphia chromosome positive OR bcr positive
        No late chronic phase, accelerated phase, or blastic phase CML

        PATIENT CHARACTERISTICS: Age: 12 and over Performance status: Zubrod 0-2 Life expectancy:
        Not specified Hematopoietic: Not specified Hepatic: Bilirubin less than 2 mg/dL Renal:
        Creatinine less than 2 mg/dL Cardiovascular: No severe heart disease Other: No psychoses
        Not pregnant or nursing Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY: Biologic therapy: Less than 1 month of prior interferon alfa
        Chemotherapy: Less than 1 month of prior cytarabine Prior hydroxyurea allowed Endocrine
        therapy: Not specified Radiotherapy: Not specified Surgery: Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hagop M. Kantarjian, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>April 29, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2004</study_first_posted>
  <last_update_submitted>July 27, 2012</last_update_submitted>
  <last_update_submitted_qc>July 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>Philadelphia chromosome positive chronic myelogenous leukemia</keyword>
  <keyword>Homoharringtonine</keyword>
  <keyword>HHT</keyword>
  <keyword>cephalotaxus alkaloid</keyword>
  <keyword>cytarabine</keyword>
  <keyword>Interferon Alpha 2-A</keyword>
  <keyword>Roferon-A</keyword>
  <keyword>Ara-C</keyword>
  <keyword>DepotCyt</keyword>
  <keyword>Cytosine Arabinosine Hydrochloride</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Homoharringtonine</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Harringtonines</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

